

Patent Updates

Suven Life Sciences secures Product Patents in Eurasia and Mexico

HYDERABAD, INDIA (January 13, 2021) – Suven Life Sciences Ltd (Suven) secures one (1) Product patents from Eurasia (036480) and 1 (one) product patent from Mexico (377517) for the treatment of disorders associated with Neurodegenerative diseases and Patent s are valid through 2037.

The granted claims of the patents include the class of selective H3 inverse agonists which are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia and sleep disorders etc.

Disclaimer and Risk Statement:

Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time

Suven Life Sciences Limited